Pozen Beats Street, Waits On Key Fda Decision On Astrazeneca Drug

Shares of Pozen rose Thursday after the drug maker revealed a first quarter net loss not as bad as Wall Street analysts had projected. Next up: a decision from the U.S. Food and Drug Administration that should really move the Chapel Hill company’s stock price – either up or down.

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News